OTCMKTS:MEDIF - MediPharm Labs Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.78
  • Forecasted Upside: 421.53 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.15
+0.30 (1.20%)

This chart shows the closing price for MEDIF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MediPharm Labs Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MEDIF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MEDIF

Analyst Price Target is $0.78
▲ +421.53% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for MediPharm Labs in the last 3 months. The average price target is $0.78, with a high forecast of $0.80 and a low forecast of $0.75. The average price target represents a 421.53% upside from the last price of $0.15.

This chart shows the closing price for MEDIF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 3 investment analysts is to hold stock in MediPharm Labs. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/16/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/14/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/13/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/13/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
6/11/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/9/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/8/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/16/2021Canaccord GenuityDowngradeBuy ➝ Hold
11/16/2021Alliance Global PartnersDowngradeBuy ➝ Neutral
8/16/2021Alliance Global PartnersLower Price TargetBuy ➝ BuyC$1.00 ➝ C$0.80
5/18/2021Canaccord GenuityLower Price TargetBuyC$1.00 ➝ C$0.75
5/18/2021Alliance Global PartnersLower Price TargetBuyC$1.25 ➝ C$1.00
4/16/2021BMO Capital MarketsInitiated CoverageMarket Perform
4/1/2021Canaccord GenuityLower Price TargetBuy$1.75 ➝ $1.00
11/17/2020Canaccord GenuityLower Price TargetBuy$2.50 ➝ $1.75
11/16/2020Roth CapitalLower Price TargetBuy$2.00 ➝ $1.00
11/2/2020Alliance Global PartnersInitiated CoverageBuy
9/3/2020Canaccord GenuityReiterated RatingBuy$2.25
6/19/2020MackieDowngradeHold$1.75
6/18/2020Pi FinancialDowngradeHold$1.75
9/23/2019Canaccord GenuitySet Price TargetBuy$8.50
(Data available from 12/9/2016 forward)

News Sentiment Rating

0.33 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/13/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/12/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2021
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/11/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/10/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/10/2021
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/9/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/9/2021

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

MediPharm Labs logo
MediPharm Labs Corp. is medicinal cannabis company, which engages in the pharmaceutical grade production of cannabis oil products. The company focuses on the downstream secondary extraction methodology, distillation, and cannabinoid isolation and purification. It supplies raw materials, formulations, processing, and packaging for the creation of ready-to-sell derivative products. The company was founded by Patrick McCutcheon in 2015 and is headquartered in Barrie, Canada.
Read More

Today's Range

Now: $0.15
Low: $0.15
High: $0.16

50 Day Range

MA: $0.20
Low: $0.15
High: $0.26

52 Week Range

Now: $0.15
Low: $0.15
High: $0.79

Volume

291,797 shs

Average Volume

461,370 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of MediPharm Labs?

The following sell-side analysts have issued stock ratings on MediPharm Labs in the last year: Alliance Global Partners, BMO Capital Markets, and Canaccord Genuity.
View the latest analyst ratings for MEDIF.

What is the current price target for MediPharm Labs?

2 Wall Street analysts have set twelve-month price targets for MediPharm Labs in the last year. Their average twelve-month price target is $0.78, suggesting a possible upside of 421.5%. Alliance Global Partners has the highest price target set, predicting MEDIF will reach $0.80 in the next twelve months. Canaccord Genuity has the lowest price target set, forecasting a price of $0.75 for MediPharm Labs in the next year.
View the latest price targets for MEDIF.

What is the current consensus analyst rating for MediPharm Labs?

MediPharm Labs currently has 3 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MEDIF, but not buy more shares or sell existing shares.
View the latest ratings for MEDIF.

How do I contact MediPharm Labs' investor relations team?

MediPharm Labs' physical mailing address is 151 John Street, Barrie, ON L4N. The company's listed phone number is (705) 719-7425. The official website for MediPharm Labs is www.medipharmlabs.com.